Skip to main content
TipRanks
Go Ultimate75% OFF

Capricor Therapeutics (CAPR) AI Stock Analysis

1,417 Followers
CAPR

Capricor Therapeutics

(NASDAQ:CAPR)

Select Model
Rating:55Neutral
Price Target:$8.50▲(1.07% Upside)
Action:reiterated
Date:11/13/26

CAPR’s score is held back primarily by weak financial performance (no current revenue, large and worsening losses, and significant cash burn). Offsetting this are a constructive technical setup and a relatively positive earnings-call backdrop driven by HOPE-3 efficacy/safety updates and active launch preparation, though the pending FDA decision and rising expenses remain key risks.

Positive Factors
Clinical efficacyDeramiocel has produced statistically significant and clinically meaningful evidence in the pivotal HOPE-3 program, with supportive integrated and extension analyses. If approved, this differentiated efficacy could support adoption in a serious disease with substantial unmet need and strengthen the company’s long-term commercial position.
Negative Factors
No recurring revenue and sustained lossesThe company remains pre-commercial, with no recurring product revenue to offset substantial operating costs. Deepening losses and strongly negative free cash flow increase reliance on external financing, potentially limiting strategic flexibility and creating dilution or funding pressure before commercial revenue becomes meaningful.

Capricor Therapeutics (CAPR) vs. SPDR S&P 500 ETF (SPY)

-100%0%100%200%300%400%500%600%CAPR+47.80%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$487.04M
Dividend Yield
―
Average Volume (3M)
4.69M
Price to Earnings (P/E)
-3.3
Beta (1Y)
1.93
Revenue Growth
-100.00%
EPS Growth
-47.08%
Country
US
Employees
231
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Capricor Therapeutics Business Overview & Revenue Model

Company Description

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which re...

How the Company Makes Money

As a clinical-stage biotechnology company, Capricor has historically generated little to no recurring revenue from product sales because its lead candidates have been in development and not broadly commercialized. When revenue is present, it is typic...

Capricor Therapeutics Earnings Call Summary

Earnings Call Date:Nov 10, 2026(Q3-2026)|% Change Since:-5.19%|Next Earnings Date:Mar 11, 2027
Earnings Call SentimentPositive

The call was predominantly positive, supported by a statistically significant HOPE-3 primary endpoint, favorable two-year extension and integrated-trial data, positive safety experience, cardiac-data recognition, FDA review progress, launch preparation, manufacturing readiness, and a cash runway of at least 12 months. Key negatives were the still-pending FDA decision, the ongoing NS Pharma dispute, no recognized revenue, higher operating expenses, larger net losses, a nonsignificant overall ejection-fraction result, and a 10% workforce reduction. The highlights significantly outweighed the lowlights.

Positive Updates

BLA Advances Through Final FDA Review
FDA agreed to review additional data and a major amendment to the BLA, extending the PDUFA target action date to November 22, 2026. The August amendment included approximately 30,000 pages of documents, reports, tables, listings, files, and data sets, including 24-month HOPE-3 open-label extension data, sensitivity and robustness analyses, and an integrated summary of efficacy from HOPE-2 and HOPE-3. All requested information has been submitted and the review remains ongoing.

Negative Updates

Overall Ejection Fraction Result Did Not Reach Statistical Significance
Across all patients in HOPE-3, the difference in ejection fraction compared with placebo did not reach statistical significance. Management stated that the statistically significant benefit was observed in the subgroup of patients with existing cardiomyopathy.

Company Guidance

Management said the FDA review remains ongoing with the PDUFA target action date extended to November 22, 2026, after submission of an amendment containing approximately 30,000 pages, and the proposed refined indication is for patients with age greater than 9 years old; commercial readiness is underway across distribution, patient support, market access, medical affairs, and physician education, while the San Diego GMP facility is ready for an initial launch, with the first-floor clean room able to meet the needs of 250 patients per year or around 1000 doses per year and the second floor expected to support 2,000 to 2500 patients or up to 10,000 doses per year operating at full capacity, with validation targeted for the first half of 2020; the company estimates approximately 15,000 people in The US are living with DMD, roughly 2-thirds are ages 9 and older, expects arbitration to commence in mid-2027, reduced its workforce by approximately 10% in the third quarter, reported approximately $198.5 million in cash, cash equivalents, restricted cash and marketable securities as of September 30, 2026, and believes its existing cash, cash equivalents and marketable securities are sufficient to fund operations for at least the next 12 months.

Capricor Therapeutics Financial Statement Overview

Summary

Financials are weak overall: revenue is inconsistent and falls to zero in 2025 annual and TTM, losses are large and worsening (TTM EBIT -$153.6M; TTM net loss -$147.5M), and cash burn is heavy with deeply negative free cash flow (TTM -$146.3M). The balance sheet provides some cushion via meaningful equity, but rising leverage in TTM increases risk if burn persists.

Income Statement

18Very Negative

Balance Sheet

54Neutral

Cash Flow

27Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue0022.27M25.18M2.55M244.90K
Gross Profit00-27.70M-11.27M-19.27M244.90K
EBITDA1.16B-100.11M-39.04M-21.22M-28.49M-19.78M
Net Income-147.50M-105.04M-40.47M-22.29M-29.02M-20.02M
Balance Sheet
Total Assets330.37M355.95M170.48M58.73M50.09M41.33M
Cash, Cash Equivalents and Short-Term Investments197.58M318.13M151.52M39.49M41.42M34.89M
Total Debt92.23M17.94M4.83M5.61M5.94M6.25M
Total Liabilities120.61M50.16M25.02M36.13M38.31M9.96M
Stockholders Equity209.76M305.79M145.46M22.60M11.79M31.37M
Cash Flow
Free Cash Flow-146.29M-72.72M-41.53M-27.64M1.56M-18.01M
Operating Cash Flow-119.99M-69.81M-40.00M-25.60M4.92M-16.81M
Investing Cash Flow-100.41M97.48M-116.18M5.11M-35.07M-1.20M
Financing Cash Flow246.13M248.89M152.77M25.58M4.87M20.23M

Capricor Therapeutics Technical Analysis

Technical Analysis SentimentNegative
Last Price8.41

Price Trends

50DMA8.07Positive
100DMA10.15Negative
200DMA19.81Negative

Market Momentum

MACD0.47Negative
RSI50.65Neutral
STOCH26.33Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CAPR, the sentiment is Negative. The current price of 8.41 is above the 20-day moving average (MA) of 7.87, above the 50-day MA of 8.07, and below the 200-day MA of 19.81, indicating a neutral trend. The MACD of 0.47 indicates Negative momentum. The RSI at 50.65 is Neutral, neither overbought nor oversold. The STOCH value of 26.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CAPR.

Capricor Therapeutics Risk Analysis

Capricor Therapeutics disclosed 32 risk factors in its most recent earnings report. Capricor Therapeutics reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.We have a history of net losses, and we expect losses to continue for the foreseeable future. In addition, a number of factors may cause our operating results to fluctuate on a quarterly and annual basis, which may make it difficult to predict our future performance.Q3, 2026
2.If we enter into strategic partnerships, we may be required to relinquish important rights to and control over the development of our product candidates or otherwise be subject to terms unfavorable to us.Q3, 2026
3.We are building commercial capabilities and a corporate compliance program in preparation for the potential launch of Deramiocel, and we may be unable to do so effectively, on a timely basis or at all.Q3, 2026

Capricor Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CAPR against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
CAPRCAPR55Neutral$488.98M-3.26-56.71%―-100.00%-47.08%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
RGNXRGNX51Neutral$478.73M-2.23-203.98%―-4.59%8.03%
ABEOABEO47Neutral$148.58M-2.30-44.82%―9652.75%-172.49%
SLDBSLDB44Neutral$695.33M-3.49-67.78%――28.59%
LXEOLXEO43Neutral$236.36M-2.33-45.29%――53.48%
RCKTRCKT42Neutral$235.60M-15.11-5.34%――93.49%

* Healthcare Sector Average

Performance Comparison

0%200%400%CAPRRCKTABEORGNXSLDBLXEODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CAPR and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CAPRCapricor Therapeutics, Inc.8.412.6445.75%
RCKTRocket Pharma2.11-0.77-26.74%
ABEOAbeona Therapeutics Inc2.60-1.60-38.10%
RGNXRegenXBio Inc.7.24-3.69-33.76%
SLDBSolid Biosciences6.231.7539.06%
LXEOLexeo Therapeutics, Inc.2.85-6.23-68.59%

Capricor Therapeutics Corporate Events

Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance

Capricor Therapeutics Faces FDA Delay for Deramiocel Review

Negative
Aug 24, 2026

On August 24, 2026, Capricor Therapeutics announced that the U.S. Food and Drug Administration extended the Prescription Drug User Fee Act target action date for its Biologics License Application for Deramiocel, an investigational cell therapy for Du...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026